Advanced search
Start date
Betweenand

Improving of human fragment antibodies (scFvs) specific for animals' venoms

Grant number: 18/14158-9
Support type:Scholarships abroad - Research Internship - Post-doctor
Effective date (Start): November 15, 2018
Effective date (End): November 14, 2019
Field of knowledge:Health Sciences - Medicine
Principal Investigator:Eliane Candiani Arantes Braga
Grantee:Felipe Augusto Cerni
Supervisor abroad: Andreas Hougaard Laustsen
Home Institution: Faculdade de Medicina de Ribeirão Preto (FMRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil
Local de pesquisa : Technical University of Denmark (DTU), Denmark  
Associated to the scholarship:17/14035-1 - Improving of human fragment antibodies (scFvs) specific for animals' venoms, BP.PD

Abstract

The production of monoclonal antibodies (mAbs) was first described in 1975, with the discovery of the hybridoma technique. Although the hybridoma technique was described in 1975, only 10 years later, in 1985, the first monoclonal antibodies were released for therapeutic use in humans. However, only after the optimization of some techniques of these mAbs, the pharmaceutical market with monoclonal antibodies had a remarkable growth. Among the optimizations, we can highlight the recombinant DNA technology and the Phage Display technique. Recently, the representation of the monoclonal antibodies (whether murine, chimeric, humanized or human) in the pharmaceutical market is a reality, being used as the most advanced therapies for the treatment of a diversity of diseases (e.g. cancer, allergy, autoimmune diseases). With 47 mAbs already marketed in 2017, there is an expectation of more than 70 in 2020. Dr. Barbosa's group has been working with monoclonal human fragment antibodies targeting venoms for many years. Using Phage Display technology, the Barbosa's laboratory produced scFv (single-chain fragment variable) human antibodies to many venoms - Serrumab, Bothrumab, Crotumab, Lachesumab, Micrurumab and Afribumab. In this way, the group aim is to produce better antivenoms (new genetarion of antivenoms), in other words, to replace the use of heterologous antivenoms used for more than a century. However, before these antibodies reach the market, they still need to be improved regarding affinity, formats, as well as, they need some complementary tests. Therefore, the present study will improve the affinity and the formats of the Serrumab and Afribumab antibodies.

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
PUCCA, MANUELA B.; CERNI, FELIPE A.; OLIVEIRA, ISADORA S.; JENKINS, TIMOTHY P.; ARGEMI, LIDIA; SORENSEN, CHRISTOFFER V.; AHMADI, SHIRIN; BARBOSA, JOSE E.; LAUSTSEN, ANDREAS H. Bee Updated: Current Knowledge on Bee Venom and Bee Envenoming Therapy. FRONTIERS IN IMMUNOLOGY, v. 10, SEP 6 2019. Web of Science Citations: 3.
PUCCA, MANUELA B.; CERNI, FELIPE A.; JANKE, RAHEL; BERMUDEZ-MENDEZ, ERICK; LEDSGAARD, LINE; BARBOSA, JOSE E.; LAUSTSEN, ANDREAS H. History of Envenoming Therapy and Current Perspectives. FRONTIERS IN IMMUNOLOGY, v. 10, JUL 10 2019. Web of Science Citations: 1.
OLIVEIRA, ISADORA S.; FERREIRA, ISABELA G.; ALEXANDRE-SILVA, GABRIEL M.; CERNI, FELIPE A.; CREMONEZ, CAROLINE M.; ARANTES, ELIANE C.; ZOTTICH, UMBERTO; PUCCA, MANUELA B. Scorpion toxins targeting Kv1.3 channels: insights into immunosuppression. Journal of Venomous Animals and Toxins including Tropical Diseases, v. 25, APR 15 2019. Web of Science Citations: 1.

Please report errors in scientific publications list by writing to: cdi@fapesp.br.